NovaBridge Biosciences
F:0VY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
NovaBridge Biosciences
F:0VY
|
US |
|
V
|
Vinci SA
DUS:SQU
|
FR |
|
H
|
Heidelberg Materials AG
XMUN:HEI
|
DE |
|
F
|
Fino Inc
KOSDAQ:033790
|
KR |
Intrinsic Value
Is 0VY undervalued or overvalued?
See the intrinsic value estimate for
NovaBridge Biosciences and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What NovaBridge Biosciences Does
I-Mab is a clinical-stage biopharmaceutical company that develops antibody-based medicines, mainly for cancer and autoimmune disease. It does not sell consumer products; its business is to discover or in-license drug candidates, run clinical trials, and work toward regulatory approval and eventual commercialization of those medicines.
- Headquarters
- United States of America US
- Employees
- 30
- IPO date
- Jan 17, 2020
Earnings Waterfall
NovaBridge Biosciences
The intrinsic value for
NovaBridge Biosciences (0VY) under the Base Case is hidden EUR.
Compared with the current market price of 0.93 EUR, the stock appears hidden.